Lysophosphatidic acid, a disintegrin and metalloprotease-17 and heparin-binding epidermal growth factor-like growth factor in ovarian cancer: the first word, not the last.
Braun
Ada H
AH
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA. ada.h.braun@vanderbilt.edu
Coffey
Robert J
RJ
D051722:ADAM Proteins / Q000378:metabolism*; D000072198:ADAM17 Protein; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004815:Epidermal Growth Factor / Q000378:metabolism*; D005260:Female; D066257:Heparin-binding EGF-like Growth Factor; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008246:Lysophospholipids / Q000502:physiology*; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents; C587883:HBEGF protein, human; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D008246:Lysophospholipids; D004815:Epidermal Growth Factor; D051722:ADAM Proteins; D000072198:ADAM17 Protein; C032881:lysophosphatidic acid